— Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer by Year End — CAMBRIDGE, Mass., May 10, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results